Drug Profile


Alternative Names: BA-168; BritLofex; Lofexidine hydrochloride; MDL-14042; MDL-14042A; RMI-14042A

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Britannia Pharmaceuticals
  • Developer Britannia Pharmaceuticals; National Institute on Drug Abuse; US WorldMeds
  • Class Antihypertensives; Chlorobenzenes; Imidazolines; Phenyl ethers; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Opioid abuse

Highest Development Phases

  • Marketed Opioid abuse

Most Recent Events

  • 05 Sep 2017 US WorldMeds enters into a manufacturing agreement with Catalent Pharma Solutions
  • 05 Sep 2017 Lofexidine receives Fast Track designation for Opioid abuse [PO,Tablet] in USA
  • 01 Jun 2016 US WorldMeds initiates a phase I pharmacokinetic trial for Opioid abuse in USA (NCT02801357)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top